ExploreWatchlistsPricing
  1. JP-listed companies
  2. Nano Holdings, Inc.
  3. Financials
  4. Revenue

Nano Holdings, Inc. (4571)

Market cap
¥10.6B
P/E ratio
-10.2x
NANO MRNA develops RNA-based drug candidates including mRNA and siRNA therapies, then licenses them to pharmaceutical companies for late-stage development and commercialization.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRevenue (Million JPY)YoY (%)
Mar 31, 2025109-19.92%
Mar 31, 2024136-32.98%
Mar 31, 2023202-23.42%
Mar 31, 2022264-15.72%
Mar 31, 2021313-43.35%
Mar 31, 2020553+11.32%
Mar 31, 2019497+91.72%
Mar 31, 2018259+18.47%
Mar 31, 2017219-10.13%
Mar 31, 2016243-63.99%
Mar 31, 2015676+43.12%
Mar 31, 2014472+26.33%
Mar 31, 2013374+7.92%
Mar 31, 2012346

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat